Agashe Vikas M, Rodrigues Camilla, Soman Rajiv, Shetty Anjali, Deshpande R B, Ajbani Kanchan, Pingle Jitendra, Agashe Mandar, Patil Hitendra, Raghuwanshi Sagar, Gundavda Manit, Gite Raju, Jakkan Mithun, Mishra Amit, Menon Aditya
Department of Orthopaedics, P D Hinduja National Hospital and MRC, Mahim, Mumbai, Maharashtra India.
Agashe Maternity and Surgical Nursing Home, Kurla, Mumbai, Maharashtra India.
Indian J Orthop. 2020 Jul 25;54(Suppl 1):60-70. doi: 10.1007/s43465-020-00202-7. eCollection 2020 Sep.
In the era of increasing drug resistance in pulmonary tuberculosis (TB), it is prudent to assess causes of poor response to anti tubercular therapy (ATT) and drug sensitivity pattern (DSP) in osteoarticular TB.
As a part of Bombay Orthopaedic society's research project, members were asked to refer non responders to ATT to our institute. Cases were enrolled from October 2010 to March 2014. Deep tissue samples were obtained in all but five cases and subjected to a battery of tests including histopathology (HPE) and TB culture and sensitivity. The DSP was compared with the study performed by the principle author from 2004 to 2007 and published in 2009.
39 male and 50 female patients with a mean age of 24.85 years (2-66) were included and classified in four groups after results. (1) Culture and HPE positive-36. 24 had MDR and three XDR TB. Primary resistance to even second line drugs and deterioration of DSP since last study was noted, (2) culture negative and HPE positive-21. The cause of poor response was surgical in more than half cases, (3) non representative samples or lost to follow-up-15, (4) TB mimics-16.
There is increasing incidence of primary resistance to second line drugs, primary resistance in children and worsening of resistance patterns as compared to older studies. ATT initiation is a fateful decision and every attempt should be made to rule out TB mimics and establish DSP before initiation.
在肺结核(TB)耐药性不断增加的时代,评估骨关节炎型结核对抗结核治疗(ATT)反应不佳的原因以及药敏模式(DSP)是明智之举。
作为孟买骨科协会研究项目的一部分,成员们被要求将对抗结核治疗无反应的患者转介至我们的研究所。病例纳入时间为2010年10月至2014年3月。除5例患者外,所有患者均获取了深部组织样本,并进行了一系列检测,包括组织病理学(HPE)、结核菌培养及药敏试验。将此次的药敏模式与第一作者在2004年至2007年进行并于2009年发表的研究结果进行了比较。
纳入了39例男性和50例女性患者,平均年龄24.85岁(2 - 66岁),结果出来后分为四组。(1)培养及HPE阳性 - 36例。24例为耐多药,3例为广泛耐药结核。注意到对二线药物甚至存在原发性耐药,且自上次研究以来药敏模式有所恶化,(2)培养阴性但HPE阳性 - 21例。超过半数病例中反应不佳的原因是手术相关,(3)样本不具代表性或失访 - 15例,(4)结核疑似病例 - 16例。
与以往研究相比,二线药物原发性耐药、儿童原发性耐药的发生率不断增加,耐药模式也在恶化。开始抗结核治疗是一个关键决策,在开始治疗前应尽一切努力排除结核疑似病例并确定药敏模式。